Navigation Links
Hepatitis C Virus Patient Opportunity Exists Within Many of the Major U.S. Local Markets
Date:2/12/2009

However, Insurance Coverage of Hepatitis C Patients Is Skewed Towards Medicare and Medicaid Compared With Dominance of Private Coverage in the General Population, According to a New Analytics Tool From Decision Resources

WALTHAM, Mass., Feb. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that hepatitis C virus patient opportunity exists within many of the major U.S. local markets: Minneapolis, MN, Boston, MA and Washington DC all have large bases of untreated patients. However, hepatitis C patients often lead high-risk lifestyles and therefore are less likely to carry insurance than the general population.

The new analytics tool entitled PatientFinder: Hepatitis C Virus estimates that while 83.9 percent of the general population has medical insurance, only 67.2 percent of the hepatitis C infected population has coverage. Furthermore, the type of insurance coverage of hepatitis C patients is skewed towards Medicare and Medicaid compared with dominance of private coverage in the general population.

"Biopharmaceutical companies who are targeting hepatitis C patients in the United States need to include these unique insurance dynamics as they prioritize the states and metropolitan statistical areas in which they want to conduct clinical trials, pursue direct-to-consumer advertising and place sales reps," stated Jason LaBonte, Ph.D., vice president of new product development at Decision Resources.

Why Pharmaceutical Companies Need this Information

With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.

About PatientFinder

PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:

  • Disease-specific prevalence numbers for each U.S. state and MSA
  • Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA
  • Unique analysis of the untreated population examined through a filter of prescription (Rx) benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory--the true local measure of opportunity for pharmaceutical companies

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Announces Initiation of Phase 2b Trial of Albuferon(R) Dosed Monthly in Chronic Hepatitis C
2. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
3. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
4. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
5. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
8. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
9. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
10. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
11. Improved culture system for hepatitis C virus infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 2017 , ... NDA Partners Chairman Carl Peck, MD ... in the FDA CDRH Division of Cardiovascular, Respiratory, and Neurological Devices and Medical ... Expert Consultant. , In Dr. Spyker’s accomplished career, he held positions as Senior ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017 ... announced today expansion of its translational research program ... through establishment of laboratory facilities in San Diego.  ... San Diego BioLabs facility, a biotechnology incubator sponsored ... Sanofi. In November 2016, the Company ...
(Date:2/21/2017)... -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage ... and restore the health of patients, intends to report operational highlights ... Thursday, March 2, 2017, and to host a conference call the ... call is as follows: U.S. (toll free): 1-888-347-5280 ... ...
(Date:2/21/2017)... ... February 21, 2017 , ... During ... connected digital health applications, announced a partnership with Redox, a leader in cloud-based ... to many clinical systems while keeping data secure in the cloud. , The ...
Breaking Biology Technology:
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... 2017  Crossmatch, a leading provider of security and ... at combatting fraud, waste and abuse in assistance operations ... Action on Disaster Relief conference in Panama ... agencies and foreign assistance organizations throughout Latin ... are a largely unacknowledged problem in the foreign assistance ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
Breaking Biology News(10 mins):